China NMPA Medical Device Registration Services

Get your medical devices approved for the Chinese market with expert support across testing, clinical evaluation and China clinical trials, NMPA registration submissions, and agency interactions. Cisema helps international manufacturers navigate regulatory requirements, manage each stage of the medical device registration process, and move toward market entry with a clear regulatory strategy.

Registration dossier
Medical device regulations

Cisema's China Medical Device Registration & Filing Services

We guide you through every step of the China medical device registration process. We take care of compliance 
with NMPA requirements, advising you on the optimal market entry pathway, test methods and helping you through the whole process to achieving your medical device registration certificate.

Our services include: 

NMPA official classification
Device risk class categorization
Advice on best regulatory pathways to register
Feasibility study to review and evaluate the possibility to write a CER based on:
  • Predicate devices 
  • Overseas clinical data 
Import of samples and transport within China
Coordinate and supervise Type Tests in NMPA Accredited Laboratories supported on-site by our in-house test engineers
Write Product Technical Requirements & CER compliant with Chinese standards
Registration renewals
Chinese label drafting & UDI support
Prepare and submit new applications:
  • NMPA standard filings for class I & registrations for class II and class III devices
  • NMPA Innovative Medical Device route 
  • Hainan Medical Tourist Pilot Zone 
  • Greater Bay Area Approvals (requiring prior Hong Kong Listing)  
  • NMPA Priority Review 
  • Emergency Approval 
  • Conditional Approval 
Receipt and reply to Supplementary Notices
Change applications

Medical Device Post-Market Surveillance Services in China

Cisema supports medical device and IVD manufacturers in China with post-market surveillance and vigilance activities, helping identify emerging safety risks and maintain ongoing compliance with NMPA requirements throughout the product lifecycle.

Adverse Event Monitoring & Vigilance

Monitor adverse events, complaints, and safety signals through the NMDAEM system
Review and assess adverse event reports and supporting data
Support timely adverse event reporting, submission, and tracking

Periodic Risk Evaluation & Reporting

Prepare and review Periodic Risk Evaluation Reports (PRERs)
Compile and analyze cumulative safety and risk data
Prepare annual adverse event summaries and risk analyses
Support annual QMS self-assessment reporting to NMPA

Risk Management & Corrective Action

Evaluate safety signals and emerging product risks
Support corrective and preventive actions in response to identified risks
Monitor risk mitigation measures and corrective actions for effectiveness

PMS Compliance & QMS Integration

Monitor NMPA regulations and standards affecting PMS
Support PMS-related regulatory submissions and follow-up
Integrate PMS activities into the manufacturer's quality management system

China NMPA Medical Device Risk Classification

The approval process, whether a registration or filing/notification, depends on the device’s risk classification, which is determined by the NMPA’s Medical Device Classification Catalogue, and is updated every year or so. If a product is not listed in the catalogue, manufacturers can refer to the "Rules for Medical Device Classification" or request an official classification from the NMPA.

Class I Medical Devices

Manufacturers must submit a filing or notification application with technical information, test reports, and quality documentation. Upon approval, the device is listed in the NMPA database, and a Certificate of Filing is issued with indefinite validity unless modified.

Class I Devices

Class II & III Medical Devices

Manufacturers must submit a registration application. These devices require local type testing, either a local Clinical Trial or a China compliant Clinical Evaluation Report (CER), and a Quality Management System review.

Class II & III Devices
Medical Device Registration in Singapore

NMPA Legal Agent Requirements for Foreign Manufacturers

To register medical devices in China, foreign manufacturers must first appoint a local NMPA Legal Agent to act as their representative throughout the product lifecycle. (NMPA stands for the National Medical Products Administration, which is China’s regulatory authority responsible for medical devices).

Explore Related China Medical Device Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and solutions to help your business thrive.

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.

Learn more

NMPA Type Testing

We provide end-to-end support for China type testing in NMPA-accredited laboratories. Our experienced test engineers offer on-site supervision to guarantee accurate and reliable results.

Learn more

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Learn more

NMPA Clinical Evaluation Report

CERs can avoid the need for a China clinical trial in some instances. Our experts can advise and prepare NMPA compliant CERs.

Learn more

Drug Device Combination Products

We assist with the classification, registration, and compliance of combination products in China, whether drug or device led.

Learn more

China Medical Device Quality Compliance

We help you achieve and ensure ongoing compliance with Chinese requirements.Our experts prepare and assist you for official NMPA inspections.

Learn more

Medical Device PMS & Vigilance

The NMPA is placing greater focus on Post-Market Surveillance (PMS) such as more in-market sampling inspections and regular standard changes.

Learn more

Regulatory Outsourcing

If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.

Learn more

Explore Cisema's Latest Medical Device Insights

View More

China Medical Device GMP vs ISO 13485: Key Differences Explained

Understand the key differences between China Medical Device GMP and ISO 13485, including requirements for quality management, suppliers, facilities and documentation.

October 15, 2026
China Medical Device GMP vs ISO 13485: Key Differences Explained
Two Chinese medical device technicians, a woman and a man wearing white lab coats, surgical caps, face masks, and protective gloves, stand side by side in a sterile cleanroom environment.

What Is China’s UDI System & How Does It Affect Medical Device Registration?

Learn about China's Unique Device Identification (UDI) system and how to navigate China’s evolving medical device market.

October 12, 2026
What Is China’s UDI System & How Does It Affect Medical Device Registration?

How Does GBA Real World Data Support China NMPA Approvals?

Discover how leveraging Real World Data generated in the Greater Bay Area can accelerate market entry for medical products in China.

October 12, 2026
How Does GBA Real World Data Support China NMPA Approvals?

Guide to Indonesia Medical Device Post-Registration Changes: Notification, Variation, or New Registration

Learn when medical device and IVD changes in Indonesia require a notification, variation, or new registration, and how to maintain ongoing regulatory compliance.

October 12, 2026
Guide to Indonesia Medical Device Post-Registration Changes: Notification, Variation, or New Registration

How Singapore Accelerates ASEAN Market Entry for Medical Devices, Pharma, & Cosmetics

This guide explains Singapore’s HSA regulatory system and why it is a strategic first step for entering Southeast Asian markets with medical devices, pharmaceuticals, and cosmetics.

October 12, 2026
How Singapore Accelerates ASEAN Market Entry for Medical Devices, Pharma, & Cosmetics

China Medical Device Approval Tracker: Imported Class II & III Devices

Track all imported Class II and III medical device approvals in China with this monthly updated NMPA submission tracker.

September 29, 2026
China Medical Device Approval Tracker: Imported Class II & III Devices
Previous
Previous

Catch the Latest Medical Device Regulatory News

View More

Hong Kong Requires MDACS Listing for Injectable Dermal Fillers by March 1, 2027

New requirements could affect how injectable devices, including dermal fillers, are supplied in Hong Kong’s private healthcare sector.

September 29, 2026
Hong Kong Requires MDACS Listing for Injectable Dermal Fillers by March 1, 2027

China Enacts First Healthcare Security Law: Impact on Global Medtech

China’s new Healthcare Security Law affects medical device reimbursement, health economic evidence, payment models, and digital traceability from 2027.

September 25, 2026
China Enacts First Healthcare Security Law: Impact on Global Medtech

Indonesia Mandates Pre-Shipment Halal Verification for Imported Products

BPJPH Regulation No. 4 of 2026 introduces pre-shipment halal verification and LPPH reports for imported goods starting September 2026.

September 25, 2026
Indonesia Mandates Pre-Shipment Halal Verification for Imported Products

NMPA Issues World’s First Industry Standard for Medical Devices Using/Adopting BCI Technology

China’s NMPA has released YY/T 2029–2026, establishing the world's first AI-BCI EEG dataset quality standard for medical devices ahead of its September 2027 enforcement.

September 23, 2026
NMPA Issues World’s First Industry Standard for Medical Devices Using/Adopting BCI Technology

China Issues First Ethical Guidelines for Artificial Intelligence Medical Imaging Research

China’s Science Ministry issued ethical guidelines establishing strict standards for AI medical imaging data, algorithm validation, and ethics reviews.

September 15, 2026
China Issues First Ethical Guidelines for Artificial Intelligence Medical Imaging Research

TFDA Simplifies Paperwork for Medical Device Applications in Taiwan

From October 1, 2026, TFDA will expand electronic review and stop issuing paper copies of approved labeling for Class I, II, and III medical devices in Taiwan.

September 11, 2026
TFDA Simplifies Paperwork for Medical Device Applications in Taiwan
Previous
Previous

Ready to Navigate Complexity & Achieve Success in China & Asia Pacific?

Let Cisema help turn your plans into reality.

Request Proposal